Abstract:9114 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC). However, patients treated with EGFR-TKIs had a median progression-free survival (PFS) of only 8 to 18 months. The occurrence of acquired resistance greatly limits the survival benefit of TKI for NSCLC patients. Extensive efforts have been paid to find a well-tolerated drug or treatment that works before acquired resistance to EGFR-TKI with low toxicity. Focusing on clinical trials of targeted combination radiotherapy, we observed some encouraging results. Methods: Stage IV NSCLC patients with EGFR sensitive mutation (19DEL or 21L858R) have received first-line EGFR TKIs treatment and achieved stable disease or partial response have been enrolled in this prospective, multicenter, randomized controlled, phaseIIstudy. Recruited from 4 hospitals in China, patients were divided into two groups: Stereotactic Body Radiation Therapy (SBRT) combined with TKIs group as the experimental and TKIs treatment group as an active comparator. The primary endpoint is PFS, and the secondary endpoint aims to overall survival (OS) and safety. To further confirmed these clinical observations in patients, xenograft experiments in nude mice were conducted. To examine the specific mechanism, transcriptome sequencing analysis was performed. Results: Between Mar 2015 and Mar 2018, A total of 61 patients who met the inclusion criteria were randomized to the TKI group and SBRT combined group. The median PFS of the TKI group and SBRT combined group were 9.0 vs 17.6 months (p = 0.016). Meanwhile, the median OS were 23.2 vs 33.6 months (p = 0.026). The total number of patients with T790m was 30(49.1%), and the incidence of T790M did not differ between the two groups. Toxicity data and subgroup analyses including different radiation sites will be presented at the conference. As for the xenograft experiments, data on tumor regression and time of drug resistance of early radiotherapy group was clearly superior to others. Transcriptome sequencing analysis found expression of c-Fos was the key point that led to the phenomena. Conclusions: The addition of SBRT significantly delayed the onset of EGFR TKIs acquired resistance and prolonged the PFS and OS of patients. Radiotherapy for the primary site alone might be superior to metastatic sites. Treatment-related adverse events were generally safe and controllable. The oncogenic role of c-Fos in the effect of radiotherapy on gefitinib resistance and promoting the proliferation of NSCLC cells is confirmed. Clinical trial information: NCT03595644.

The Different Radiosensitivity when Combining Erlotinib with Radiation at Different Administration Schedules Might Be Related to Activity Variations in C-Met-pi3k-akt Signal Transduction.

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody

Icotinib Hydrochloride Enhances Chemo- And Radiosensitivity By Inhibiting Egfr Signaling And Attenuating Rad51 Expression And Function In Hela S3 Cells

Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.

Radiosensitizing effects of gefitinib at different administration times in vitro

Enhancement of Radiation Sensitivity by Erlotinib and Celecoxib in A549 Human Lung Cancer Cell Line

Gefitinib at different administration time in radiosensitizing lung adenocarcinoma cells in vitro

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.

PI3Kα Inhibitors Sensitize Esophageal Squamous Cell Carcinoma to Radiation by Abrogating Survival Signals in Tumor Cells and Tumor Microenvironment.

Radiosensitizing Effects of h-R3 with Different Time Series of Administration on Human Lung Cancer Cells Expressing Various EGFR Levels

Differential Response to EGFR- and VEGF-targeted Therapies in Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma and Related Metastases

Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.

PI3K/AKT Inhibitor Influence on the Radiosensitivity of Breast Cancer Cells

MTOR Inhibition Reversed Drug Resistance after Combination Radiation with Erlotinib in Lung Adenocarcinoma

Combination of S-1 and Gefitinib Increases the Sensitivity to Radiotherapy in Lung Cancer Cells

P2.05-005 Mechanism of Radiotherapy in Reduction/Delay of T790M-Mediated EGFR TKI Resistance: Topic: Biology

Phosphoinositide-3-kinase Inhibition Enhances Radiosensitization of Cervical Cancer in Vivo.

Primarily Analysis of Radiation Pneumonitis and Its Risk Factors in Patients with Non-Small Cell Lung Cancer Treated with Concurrent Erlotinib and Thoracic Radiation Therapy

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy